We put the "MD" in MaaDtitan. Our roster includes a licensed physician with Ivy League credentials and a Ph.D. lab researcher with several publications as lead author and principal investigator-- who left prior careers to lend domain experience to our enterprise.
We have healthcare investing experience. Our Principal is a seasoned investment professional, having spent nearly a decade investing in biopharma companies at various prestigious firms on Wall Street and in Silicon Valley.
We know innovation and entrepreneurship. Our Principal has filed patent applications on commercializable technology, spun technology out of academia, and founded and funded his own startups.
Recent projects proposed include:
--evaluating a biopharmaceutical company's business plan and pitch to "buyside" institutional investors
--evaluating a biopharmaceutical company's drug pipeline
--analysis of a key catalyst event for a drug asset (e.g., clinical trial readout, regulatory decision)
--analysis of a portfolio of publicly traded biopharmaceutical companies
--delineating asset management mechanisms at investment firms
--evaluating cutting-edge technology (e.g., gene therapy, Artificial Intelligence (AI), microbiome, cell-free DNA diagnostics, personalized medicine, and anti-aging therapeutics) and potential applications
--open-ended phone consultations on various clinical topics
Projects can be tailored to your particular needs after an initial consultation... So, please ask!
We will work for cash, for equity, and mostly we work for you!
We have healthcare investing experience. Our Principal is a seasoned investment professional, having spent nearly a decade investing in biopharma companies at various prestigious firms on Wall Street and in Silicon Valley.
We know innovation and entrepreneurship. Our Principal has filed patent applications on commercializable technology, spun technology out of academia, and founded and funded his own startups.
Recent projects proposed include:
--evaluating a biopharmaceutical company's business plan and pitch to "buyside" institutional investors
--evaluating a biopharmaceutical company's drug pipeline
--analysis of a key catalyst event for a drug asset (e.g., clinical trial readout, regulatory decision)
--analysis of a portfolio of publicly traded biopharmaceutical companies
--delineating asset management mechanisms at investment firms
--evaluating cutting-edge technology (e.g., gene therapy, Artificial Intelligence (AI), microbiome, cell-free DNA diagnostics, personalized medicine, and anti-aging therapeutics) and potential applications
--open-ended phone consultations on various clinical topics
Projects can be tailored to your particular needs after an initial consultation... So, please ask!
We will work for cash, for equity, and mostly we work for you!